Literature DB >> 32437563

Born to RUNX1.

Pamela J Sung1, Daria V Babushok1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32437563      PMCID： PMC7243147          DOI： 10.1182/blood.2020006152

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   25.476


× No keyword cloud information.
  10 in total

1.  RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.

Authors:  V I Gaidzik; V Teleanu; E Papaemmanuil; D Weber; P Paschka; J Hahn; T Wallrabenstein; B Kolbinger; C H Köhne; H A Horst; P Brossart; G Held; A Kündgen; M Ringhoffer; K Götze; M Rummel; M Gerstung; P Campbell; J M Kraus; H A Kestler; F Thol; M Heuser; B Schlegelberger; A Ganser; L Bullinger; R F Schlenk; K Döhner; H Döhner
Journal:  Leukemia       Date:  2016-11       Impact factor: 11.528

2.  Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies.

Authors:  Michael W Drazer; Sabah Kadri; Madina Sukhanova; Sushant A Patil; Allison H West; Simone Feurstein; Dalein A Calderon; Matthew F Jones; Caroline M Weipert; Christopher K Daugherty; Adrián A Ceballos-López; Gordana Raca; Mark W Lingen; Zejuan Li; Jeremy P Segal; Jane E Churpek; Lucy A Godley
Journal:  Blood Adv       Date:  2018-01-23

3.  Germline DDX41 mutations define a significant entity within adult MDS/AML patients.

Authors:  Marie Sébert; Marie Passet; Anna Raimbault; Ramy Rahmé; Emmanuel Raffoux; Flore Sicre de Fontbrune; Marco Cerrano; Samuel Quentin; Nadia Vasquez; Mélanie Da Costa; Nicolas Boissel; Hervé Dombret; Régis Peffault de Latour; Gérard Socié; Raphaël Itzykson; Pierre Fenaux; Jean Soulier; Lionel Adès; Emmanuelle Clappier
Journal:  Blood       Date:  2019-10-24       Impact factor: 22.113

4.  Germline alterations in a consecutive series of acute myeloid leukemia.

Authors:  Ulla Wartiovaara-Kautto; Elina A M Hirvonen; Esa Pitkänen; Caroline Heckman; Janna Saarela; Kaisa Kettunen; Kimmo Porkka; Outi Kilpivaara
Journal:  Leukemia       Date:  2018-04-10       Impact factor: 11.528

5.  Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

Authors:  Erdogan Taskesen; Lars Bullinger; Andrea Corbacioglu; Mathijs A Sanders; Claudia A J Erpelinck; Bas J Wouters; Sonja C van der Poel-van de Luytgaarde; Frederik Damm; Jürgen Krauter; Arnold Ganser; Richard F Schlenk; Bob Löwenberg; Ruud Delwel; Hartmut Döhner; Peter J M Valk; Konstanze Döhner
Journal:  Blood       Date:  2010-12-21       Impact factor: 22.113

6.  Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

Authors:  R Coleman Lindsley; Wael Saber; Brenton G Mar; Robert Redd; Tao Wang; Michael D Haagenson; Peter V Grauman; Zhen-Huan Hu; Stephen R Spellman; Stephanie J Lee; Michael R Verneris; Katharine Hsu; Katharina Fleischhauer; Corey Cutler; Joseph H Antin; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2017-02-09       Impact factor: 91.245

Review 7.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

8.  ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants.

Authors:  Xi Luo; Simone Feurstein; Shruthi Mohan; Christopher C Porter; Sarah A Jackson; Sioban Keel; Michael Chicka; Anna L Brown; Chimene Kesserwan; Anupriya Agarwal; Minjie Luo; Zejuan Li; Justyne E Ross; Panagiotis Baliakas; Daniel Pineda-Alvarez; Courtney D DiNardo; Alison A Bertuch; Nikita Mehta; Tom Vulliamy; Ying Wang; Kim E Nichols; Luca Malcovati; Michael F Walsh; Lesley H Rawlings; Shannon K McWeeney; Jean Soulier; Anna Raimbault; Mark J Routbort; Liying Zhang; Gabriella Ryan; Nancy A Speck; Sharon E Plon; David Wu; Lucy A Godley
Journal:  Blood Adv       Date:  2019-10-22

9.  High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML.

Authors:  Laura Simon; Jean-François Spinella; Chi-Yuan Yao; Vincent-Philippe Lavallée; Isabel Boivin; Geneviève Boucher; Eric Audemard; Marie-Eve Bordeleau; Sébastien Lemieux; Josée Hébert; Guy Sauvageau
Journal:  Blood       Date:  2020-05-21       Impact factor: 22.113

10.  Patterns and functional implications of rare germline variants across 12 cancer types.

Authors:  Charles Lu; Mingchao Xie; Michael C Wendl; Jiayin Wang; Michael D McLellan; Mark D M Leiserson; Kuan-Lin Huang; Matthew A Wyczalkowski; Reyka Jayasinghe; Tapahsama Banerjee; Jie Ning; Piyush Tripathi; Qunyuan Zhang; Beifang Niu; Kai Ye; Heather K Schmidt; Robert S Fulton; Joshua F McMichael; Prag Batra; Cyriac Kandoth; Maheetha Bharadwaj; Daniel C Koboldt; Christopher A Miller; Krishna L Kanchi; James M Eldred; David E Larson; John S Welch; Ming You; Bradley A Ozenberger; Ramaswamy Govindan; Matthew J Walter; Matthew J Ellis; Elaine R Mardis; Timothy A Graubert; John F Dipersio; Timothy J Ley; Richard K Wilson; Paul J Goodfellow; Benjamin J Raphael; Feng Chen; Kimberly J Johnson; Jeffrey D Parvin; Li Ding
Journal:  Nat Commun       Date:  2015-12-22       Impact factor: 14.919
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.